首页> 外文期刊>British Journal of Pharmacology >Reversal by NPY, PYY and 3-36 molecular forms of NPY and PPY of intracisternal CRF-induced inhibition of gastric acid secretion in rats
【24h】

Reversal by NPY, PYY and 3-36 molecular forms of NPY and PPY of intracisternal CRF-induced inhibition of gastric acid secretion in rats

机译:NPY,PYY和3-36分子形式的NPY和PPY逆转脑内CRF诱导的大鼠胃酸分泌抑制

获取原文
获取原文并翻译 | 示例
           

摘要

1. The Y receptor subtype involved in the antagonism by neuropeptide Y (NPY) of intracisternal corticotropin-releasing factor (CRF)-induced inhibition of gastric acid secretion was studied in urethane-anaesthetized rats by use of peptides with various selectivity for Y_1, Y_2 and Y_3 subtypes: NPY, a Y_1, Y_2 and Y_3 agonist, peptide YY (PYY), a Y_1 and Y_2 agonist, [Leu~(31), Pro~(34)]-NPY, a Y_1 and Y_3 agonist, NPY(3-36) and PYY(3-36), highly selective Y_2 agonists and NPY(13-36) a weak Y_2 and Y_3 agonist. Peptides were injected intracisternally 10 min before intracisternal injection of CRF (10 μg) and gastric acid secretion was measured by the flushed technique for 1 h before and 2 h after pentagastrin-(10 μg kg~(-1) h~(-1), i.v.) infusion which started 10 min after CRF injection. 2. Intracisternal injection of CRF (10 μg) inhibited by 56% gastric acid secretion stimulated by pentagastrin. Intracisternal injection of NPY and PYY (0.1-0.5 μg) did not influence the acid response to pentagastrin but blocked CRF-induced inhibition of pentagastrin-stimulated acid secretion. NPY(3-36) (0.5 μg) and PYY(3-36) (0.25 and 0.5 μg) also completely blocked the inhibitory action of CRF on pentagastrin-stimulated acid secretion. 3. [Leu~(31), Pro~(34)]-NPY (0.5-5 μg) and NPY(13-36) (0.5-5 μg) injected intracisternally did not modify gastric acid secretion induced by pentagastrin or CRF inhibitory action. 4. The sigma antagonist, BMY 14802 (1 mg kg~(-1), s.c.) did not influence the acid response to pentagastrin but prevented the antagonism by PYY(3-36) (0.5 μg) of the CRF antisecretory effect. 5. These results show that both PYY and NPY and the 3-36 forms of PYY and NPY are equipotent in blocking central CRF-induced inhibition of pentagastrin-stimulated gastric acid secretion. The structure-activity profile suggests a mediation through Y_2 receptor subtype and the involvement of sigma binding sites.
机译:1.在尿烷麻醉的大鼠中,通过对Y_1,Y_2具有不同选择性的肽,研究了神经酰胺Y(NPY)拮抗脑内促肾上腺皮质激素释放因子(CRF)诱导的胃酸分泌抑制的Y受体亚型。和Y_3亚型:NPY,Y_1,Y_2和Y_3激动剂,肽YY(PYY),Y_1和Y_2激动剂,[Leu〜(31),Pro〜(34)]-NPY,Y_1和Y_3激动剂,NPY( 3-36)和PYY(3-36)是高度选择性的Y_2激动剂,而NPY(13-36)是弱Y_2和Y_3激动剂。腹腔内注射CRF(10μg)前10 min腹腔内注射肽,并在五肽胃泌素(10μgkg〜(-1)h〜(-1)之前和之后2 h用冲洗技术测量胃酸分泌。 ,iv)在CRF注射后10分钟开始的输注。 2.颅内注射CRF(10μg)受五肽胃泌素刺激的56%胃酸分泌抑制。胸腔内注射NPY和PYY(0.1-0.5μg)不会影响对五肽胃泌素的酸反应,但会阻断CRF诱导的五肽胃泌素刺激的酸分泌抑制作用。 NPY(3-36)(0.5μg)和PYY(3-36)(0.25和0.5μg)也完全阻断了CRF对五肽胃泌素刺激的酸分泌的抑制作用。 3.脑池内注射[Leu〜(31),Pro〜(34)]-NPY(0.5-5μg)和NPY(13-36)(0.5-5μg)不会改变五肽胃泌素或CRF抑制诱导的胃酸分泌行动。 4. Sigma拮抗剂BMY 14802(1 mg kg〜(-1),皮下注射)不影响对五肽胃泌素的酸反应,但通过PYY(3-36)(0.5μg)CRF的抗分泌作用阻止了拮抗作用。 5.这些结果表明,PYY和NPY以及PYY和NPY的3-36形式均能有效阻断中央CRF对五肽胃泌素刺激的胃酸分泌的抑制作用。结构活性图表明通过Y_2受体亚型的介导和σ结合位点的参与。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号